Therefore, recently, more and more research has focused on the heat shock protein inhibitors HSP90, HSP70 and HSP40, which can inhibit both the full-length AR and its splicing variants as potential cancer therapy targets in enzalutamide-resistant prostate cancer, which is now a serious clinical challenge. This evidence concerns the gene HSP90AA1 and prostate carcinoma.